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AcetylationMetastasis associated protein 1 (MTA1) is a component of the nucleosome remodeling and deacetylating
(NuRD) complex which mediates gene silencing and is overexpressed in several cancers. We reported earlier
that resveratrol, a dietary stilbene found in grapes, can down-regulate MTA1. In the present study, we show
that PTEN is inactivated by MTA1 in prostate cancer cells. Further, we show that resveratrol promotes acety-
lation and reactivation of PTEN via inhibition of the MTA1/HDAC complex, resulting in inhibition of the Akt
pathway. In addition, we show that MTA1 knockdown is sufﬁcient to augment acetylation of PTEN indicating
a crucial role of MTA1 itself in the regulation of PTEN acetylation contributing to its lipid phosphatase activity.
Acetylated PTEN preferentially accumulates in the nucleus where it binds to MTA1. We also show that MTA1
interacts exclusively with PTEN acetylated on Lys125 and Lys128, resulting in diminished p-Akt levels. Finally,
using orthotopic prostate cancer xenografts, we demonstrate that both resveratrol treatment and MTA1
knockdown enhance PTEN levels leading to a decreased p-Akt expression and proliferation index. Taken to-
gether, our results indicate that MTA1/HDAC unit is a negative regulator of PTEN which facilitates survival
pathways and progression of prostate cancer and that resveratrol can reverse this process through its
MTA1 inhibitory function.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
“Allmen are at risk for prostate cancer. Changing the risk factors that
can be controlled, such as diet, is one way to reduce prostate cancer
risk”. Since prostate cancer is age-related and relatively slow growing
cancer, chemoprevention becomes the most promising strategy for
the future management of this disease. Consequently, bio-reactive die-
tary compounds with anticancer properties, such as resveratrol, are of
particular interest.
Resveratrol, a dietary compound found in berries, peanuts andmost-
ly in grapes and wine, is known for its cardioprotective, anti-
inﬂammatory, antioxidant and anticancer activities [1]. The anticancer
action of resveratrol involves modulation of multiple molecular targets
and pathways resulting in cell cycle arrest and apoptosis and inhibition
of angiogenesis [2–7]. However, there are serious knowledge gaps re-
garding resveratrol's epigenetic mechanisms of action.
We reported earlier on a new epigenetic target of resveratrol, the
metastasis-associated protein 1 (MTA1), which is a part of nucleosome; PTEN, phosphatase and tensin
of Mississippi Medical Center,
601 815 6072.remodeling and deacetylation (NuRD) co-repressor complex thatmedi-
ates gene silencing [8,9]. We showed that resveratrol causes apoptosis
in prostate cancer cells by inhibiting MTA1 and reversing MTA1-
mediated deacetylation of p53 [10]. In prostate cancer xenografts,
resveratrol treatment reduced mitotic activity and angiogenesis, and
in co-operation with MTA1-knockdown, showed improved response
with noticeable delay in tumor growth. Importantly, there was signiﬁ-
cantly increased levels of acetylated p53 (Ac-p53) and signiﬁcant in-
crease in apoptotic index upon resveratrol treatment [11]. These
results clearly indicated that resveratrol alters post-translational modi-
ﬁcation of tumor suppressor p53 through targeting negative epigenetic
modiﬁer MTA1. We observed an inverse relationship between MTA1
and PTEN (phosphatase and tensin homolog deleted on chromosome
10) tumor suppressor protein levels and subsequently hypothesized
that MTA1, which is abundantly accumulated in aggressive prostate
cancer and metastasis [12–14], may participate in the deacetylation
and inactivation of PTEN thereby activating downstreamAkt cell surviv-
al and migration pathways [15–18]. We further hypothesized that res-
veratrol by down-regulating MTA1 may reactivate PTEN and rescue
apoptotic pathways.
The tumor suppressor PTEN controls a variety of biological processes
by negatively regulating the PI3K/Akt cell survival pathway [15,19]. The
Pten gene is frequently mutated in prostate cancer [20]. At the same
time, hypermethylation of the Pten promoter, and reduction of PTEN
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cancers, indicating possible epigenetic mechanisms of PTEN regulation
[21]. Therefore, it is possible that in addition to a direct mutation of
the Pten gene, deregulation of PTEN protein on post-translational level
plays role in cancer initiation and progression opening therapeutically
attractive approaches for PTEN reactivation. Indeed, it has been report-
ed that PTEN can be modiﬁed by phosphorylation, oxidation,
nitrosylation and ubiquitination [15], and that all these modiﬁcations
exert negative regulatory effects on PTEN function. However, there is
limited literature on acetylation/deacetylation of PTEN and how this
modiﬁcation regulates its function.
In the current study, we provide evidence that there is an inverse re-
lationship betweenMTA1 and PTEN and that in aggressive prostate can-
cer, nuclearMTA1 interactswith acetylated PTEN and inhibits its tumor-
suppressive functions. Importantly, resveratrol can reactivate PTEN by
reversing the negative effect of MTA1/HDAC mediated deacetylation.
Our ﬁnding offers novel chemopreventive and therapeutic potential of
dietary agents for management of prostate cancer.
2. Materials and methods
2.1. Reagents
Resveratrol (Res) (3,5,4′-trihyrdoxy-trans-stilbene) and Trichostatin
A (TSA) were purchased from Sigma-Aldrich, IN, USA. SAHA
(SuberoylAnilide Hydroxamic acid) was purchased from Cayman
Chemicals, MI, USA. Resveratrol was used at 50 μM, SAHA at 10 μM
and TSA at 300 nM concentrations for all experiments unless otherwise
mentioned.
2.2. Cell culture
Humanprostate cancer cells, DU145 andPC3M(ATCC, VA, USA and a
gift from Dr. Bergan, Northwestern University, Chicago, respectively),
were cultured in RPMI 1640 containing 10% fetal bovine serum (FBS)
and 1% antibiotics (Life Technologies, NY, USA) at 37 °C and 5% CO2.
Pten+/+ and Pten−/− mouse prostate epithelial cell lines were a gift
from Dr. Tzivion, UMMC and were maintained in DMEM supplemented
with 10% FBS with 1% antibiotics at 37 °C and 5% CO2. 293T cells (ATCC,
VA, USA) were maintained in DMEM supplemented with 10% FBS with
1% antibiotics at 37 °C and 5% CO2. For experiments involving treat-
ments with resveratrol, phenol red-free media containing 10%
charcoal-stripped serum (Life Technologies, NY, USA) was used to pro-
vide steroid-free background. Cells were transferred to phenol red-free
medium one day prior to treatments. Subsequently, cells were either
treated with control (Ctrl, Ethanol/DMSO) or resveratrol (Res, 50 μM,
unless otherwise mentioned) or SAHA (10 μM) or TSA (300 nM) for
18–24 h.
2.3. Plasmids, transfections and mutagenesis
The 800 pSG5L HA-PTEN (plasmid 10750), [22] and HDAC1-Flag
(plasmid 13820) [23] plasmids were received from Addgene, MA,
USA. Myc-MTA1 construct was a kind gift from Dr. Rakesh Kumar
(George Washington University) and myc-p300 plasmid was a kind
gift from Dr. Tzivion, Cancer Institute, UMMC. For transient transfec-
tions, 293T and/or PC3M cells were plated in 10 cm dishes (BD Falcon,
Corning Life Sciences, MA, USA) to reach 80–90% conﬂuence and were
transfected with myc-MTA1, HA-PTEN, HDAC1-Flag, myc-p300 and
PTEN mutant constructs or their respective empty vectors (10 μg) in
OptiMEM (LifeTechnologies, NY, USA) using Fugene HD (Promega, WI,
USA). After 36 h, cells were harvested and immunoprecipitation (IP)
and western blot procedures were followed as described in the follow-
ing sections.
Mutant PTEN constructs were created using the Infusion HD cloning
kit (Clontech, CA, USA) following the mutagenesis protocol as permanufacturer's instructions. The following primer sequences were
used in inverse PCR reactions for amplifying the designated clones;
K125128Q Fwd 5′-tgtcaagctggacaaggacgaactggtgtaatgatatgtgcata-
3′ and Rev 5′-cttgtccagcttgacagtgaattgctgcaacatgattgtcatctt-3′,
K125128R Fwd 5′-ttcactgtagagctggaagaggacgaac-3′ and Rev 5′-
gttcgtcctcttccagctctacagtgaaaacg-3′, K402Q Fwd 5′-tacacaaatt
acacaagtctgagaattccccgatatcgcctcga-3′ and Rev 5′-tcagacttgtgt
aatttgtgtatgctgatcttcatcaaaagg-3′, K402R Fwd 5′-acaaattacaaga
gtctgagaattccccgatatcgccagctca-3′ and Rev 5′-tcagactcttgtaatt
tgtgtatgctgtctctcaaaaggttcatt-3′. The sequences in bold indicate the
mutant amino acid(s) which were veriﬁed by sequencing (Davis
Sequencing, CA, USA).
2.4. MTA1 silencing
Establishment of stable prostate cancer cell lines with MTA1 knock-
down (MTA1shRNA) was described and characterized previously
[10–12]. Brieﬂy, the expression ArrestTMGIPZ lentiviral shRNAmir
vectors expressing MTA1shRNA and non-silencing empty vector (EV)
were purchased from Open Biosystems (GE Dharmacon, CO, USA) and
virus particles were generated using 293T cells and packaging plasmid
mixture (psPAX2 and pMD2.G, Addgene, MA, USA). Stable positive
cloneswere selected using 1 μg/ml puromycin. The cell lineswere stably
transfected with luciferase (luc) and selected on G418 (neomycin,
Sigma-Aldrich, IN, USA) for high luciferase expression to be used in
vivo [11].
2.5. Western blot
Western blot analysis was performed as previously described
[10–12]. Brieﬂy, cells were harvested in chilled RIPA buffer with
protease and phosphatase inhibitors (ThermoScientiﬁc, IL, USA).
In the experiments with TSA/SAHA treatments we also used
deacetylase inhibitors in the buffer. Protein estimation was per-
formed using the Bradford reagent on a SmartSpec 3000 spectro-
photometer (BioRad, CA, USA). 70 μg protein was loaded on 10%
TGX gel, transferred to PVDF membrane, and probed with the fol-
lowing primary antibodies: Acetylated lysine (#9441), PTEN
(#9188), p-Akt (Ser473, #9271), Akt (#4691) and Erk1/2 (#4695)
(1:1000, Cell Signaling, MA, USA); MTA1 (A-11), HDAC1 (10E2)
and anti-HDAC2 (B-2) (1:200, Santa Cruz Biotechnologies, CA,
USA), β-actin (AC-15) and Lamin A (H-102) (1:1000, Santa Cruz
Biotechnologies, CA,USA), myc (hybridoma supernatant, 1:250)
and Flag (Clone M2, 1:1000, Sigma-Aldrich, IN, USA). Goat anti-
mouse or goat anti-rabbit secondary antibodies (1:2500, Sigma-
Aldrich, IN, USA) and goat anti-mouse light chain speciﬁc antibody
(1:1000, Jackson Immunoresearch, PA, USA) were used for detec-
tion. Signals were visualized using Supersignal West Dura enhanced
chemiluminescent substrate (ThermoScientiﬁc, IL, USA) on a
Chemidoc Imager (BioRad, CA, USA). Images were quantiﬁed using
ImageJ software (NIH).
2.6. Immunoprecipitation
Immunoprecipitation assays were performed using the Pierce Clas-
sic IP kit (ThermoScientiﬁc, IL, USA) as per manufacturer's instructions.
Brieﬂy, DU145 cells were plated in 150mm dishes and cultured till 70–
80% conﬂuence. 293T or PC3M cells were transfected as described in
Section 2.3. The cells were washed in DPBS (Life Technologies, NY,
USA) and harvested in 0.5 ml of IP lysis buffer (Pierce Classic IP kit)
with protease and phosphatase inhibitors (ThermoScientiﬁc, IL, USA).
Lysates were prepared with 20 strokes on a Dounce homogenizer (Sar-
torius, Goettingen, Germany) and supernatants collected after centrifu-
gation at 14,000 rpm for 10min at 4 °C (Eppendorf 5430R,NY, USA). The
lysates were incubated with 6 μg of primary antibodies or as per
manufacturer's instructions: MTA1 (H-166), HDAC1 (10E2), HDAC2
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acetyl-lysine (#9441,) on a rotating chamber overnight at 4 °C.
20 μl of Protein A/G beads (Pierce Classic IP kit, ThermoScientiﬁc,
IL, USA) was added to the lysates after washing in spin columns
and incubated for 2 h at 4 °C. The IP products were eluted in 2× sam-
ple reducing buffer with 20 mM dithiothreitol (DTT). IP elutes were
loaded on 10% TGX gels (BioRad, CA, USA) and western blot was
performed with indicated antibodies.2.7. Subcellular fractionation
Fractionations were performed using the NE-PER Nuclear and Cyto-
plasmic extraction reagent kit (Thermo Scientiﬁc, IL, USA) according to
themanufacturer's instructions. Brieﬂy, cells were harvestedwith 0.25%
trypsin-EDTA (Life Technologies, NY, USA), washed in DPBS and
pelleted by centrifugation at 12,000 rpm for 10 min at 4 °C. 200 μl of
buffer CER I was added with protease and phosphatase inhibitors to
the cell pellet and vigorously vortexed for 15 s and incubated on ice
for 10 min. Thereafter, buffer CER II (11 μl) was added and additionally
vortexed and incubated on ice for 5min. Cytoplasmic extracts were col-
lected as supernatants by centrifuging at 16,000 g for 10 min. The cell
pellet was washed thrice with 1 ml DPBS to remove cytoplasmic con-
tamination. To the nuclear pellet, 100 μl buffer NER was added and
vortexed for 15 s every 10 min for 40 min and supernatants were col-
lected by centrifuging at 16,000 g for 10 min. Protein estimations and
IP reactions were performed immediately or the extracts were stored
at−80 °C for later analysis.Fig. 1. A) MTA1 and HDAC1 and 2 are in complex. Reciprocal co-immunoprecipitations (co-IP
HDAC2 antibodies and western blot analysis was performed to detect MTA1, HDAC1 and H
MTA1, MTA2, MTA3, HDAC1 and HDAC2 protein levels in DU145 cells in a dose-dependent ma
dicated concentrations of resveratrol (Res) for 24 h. C) Graphical representation of results. The
relative to Ctrl. The means ± SE of three independent experiments are shown.2.8. Immunoﬂourescence
DU145 cells were plated on sterile cover slips in 35 mm petri
dishes (BD Falcon, Corning Life Sciences, MA, USA) so that they
were at a conﬂuence of 60–70% on the day of experiment. Cells
were ﬁxed in freshly prepared 2% chilled paraformaldehyde
(ThermoScientiﬁc, IL, USA) for 15 min at room temperature on a
rocker, washed with cold PBS and permeabilized in 0.5% TritonX-
100/PBS (Fisher Scientiﬁc, PA, USA) for 15 min and washed with
cold PBS. Non-speciﬁc binding was blocked by incubating cells
with 10% normal mouse serum, 30 min at room temperature. For
dual staining, cells were incubated ﬁrst with MTA1 antibody (1:50,
A-11, Santa Cruz Biotechnologies, CA, USA) followed by secondary
antibody Alexa 488 (1:200, Life Technologies, NY, USA) in staining-
wash buffer (5% FBS/0.5% TritonX-100/PBS) in dark for 1 h on a rock-
er. This was followed by washing and incubation with PTEN anti-
body (FL-403, 1:50, Santa Cruz Biotechnologies, CA, USA) followed
by secondary antibody Alexa 633 (1:200, Life Technologies, NY,
USA) for 1 h at room temperature. Finally cells were stained with
Propidium Iodide (PI, 10 μg/ml, Sigma-Aldrich, IN, USA) and washed
and mounted in Vectashield with DAPI (Vector Laboratories, CA,
USA). Unstained cells and cells incubated with secondary antibody
alone were used as negative controls. Images were acquired with a
63× objective on a Leica Brightﬁeld Fluorescent microscope and
Leica TCS SP2 confocal microscope and analyzed using the LAS AF
Lite software version 2.6.0 (Leica Microsystems, IL, USA). For quan-
titation of co-localization, NIS elements Imaging software version
3.10, SP3, Hotﬁx (Build 644, LO) was used.) were performed with lysates from DU145 cells using anti-MTA1, anti-HDAC1 and anti-
DAC2 respectively in IP elutes and in whole cell lysates (input). B) Resveratrol inhibits
nner. Western blot analysis of lysates from DU145 cells treated with Ethanol (Ctrl) or in-
vehicle-treated control (Ctrl) is normalized to 1 and protein level changes are expressed
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Tumor tissues from the orthotopic prostate cancer xenografts
described previously [11], were used for immunohistochemistry. Brief-
ly, male nude mice were fed with phytoestrogen-free diet, injected
orthotopically (intraprostatic) with DU145-luciferase-tagged MTA1-
expressing (Ctrl) and MTA1-knockdown (MTA1shRNA) cells. Control
group was treated with vehicle 10% DMSO and treatment group was
injected 50 mg/kg bw/day of resveratrol through intraperitoneal (i.p.)
administration. Bioluminescence signals were detected every week.
The mice were sacriﬁced at week 8 after cell inoculation. At necropsy,
prostates were excised and ﬁxed in 10% neutral-buffered formalin for
histopathological and immunohistochemical analysis.
2.10. Immunohistochemistry
Immunochemistry was performedwith 4 μm formalin-ﬁxed paraf-
ﬁn embedded tumor sections to evaluate Ki67, PTEN, MTA1 and p-Akt
levels as described previously [11–13]. The VECTASTAIN ABC Elite Kit
and the ImmPACT DAB kit (Vector Laboratories, CA, USA)were used to
visualize staining. The following antibodies were used: anti-Ki67
(1:100, Abcam, MA, USA) and anti-PTEN (1:200, Santa Cruz Biotech-
nologies, CA, USA), anti-MTA1 and anti-pAkt (1:50, Cell Signaling
Technologies, MA, USA). Images were recorded on a Nikon Eclipse
80i microscope and analyzed using the NIS elements BR 3.22.11
software.Fig. 2.MTA1 and PTEN are inversely related. A). Resveratrol inhibits MTA1 concomitantly wit
lysates from DU145 and 22Rv1 cells treatedwith Ethanol (Ctrl) or resveratrol (Res, 50 μM for D
epithelial cells from Pten null mice. Western blot analysis of lysates from Pten+/+ and Pten−
C) Resveratrol inhibits MTA1 in Pten−/− cell line. Pten+/+ and Pten−/− cells were either trea
D) Fluorescence microscopy showing co-localization of MTA1 and PTEN in DU145 cells. Cells
followed by visualization with secondary anti-rabbit Alexa 488 and anti-mouse Alexa 633 anti
croscope. Imageswere pseudo-colored in red to representMTA1 and in green to represent PTEN
in nucleus (merge, yellow). E) Subcellular localization and differential expression ofMTA1 and P
from DU145 cells is shown. Lamin A and Erk1/2 levels were used as loading controls for nuclea
distribution for MTA1, HDAC1 and HDAC2 proteins while PTEN is mostly cytoplasmic and part2.11. Statistical analysis
Statistical signiﬁcance (p values) in mean values of two-sample
comparison was determined with paired two-tailed Student's t-test. A
p-value b 0.05 was considered to be statistically signiﬁcant.3. Results
3.1. Resveratrol down-regulates components of the nucleosome remodeling
and deacetylase (NuRD) complex
We have previously shown that MTA1 physically associates with
HDAC1 in prostate cancer cells [10]. Others also demonstrated that
MTA1 interacts with both HDAC1 and HDAC2 in breast cancer cells
[24,25]. We too found that MTA1 interacts with both HDAC1 and
HDAC2, which also interact with each other in DU145 cells (Fig. 1A).
These results demonstrate that, in a physiological setting, MTA1/
HDAC1/2 occurs as a complex in prostate cancer cells. We reported ear-
lier that resveratrol down-regulates MTA1 and dissociates MTA1/
HDAC1 complex [10]. This prompted us to investigate whether resvera-
trol has any effects on HDAC1 and HDAC2 protein levels directly. Inter-
estingly, we found that resveratrol along with MTA1 inhibition
decreases MTA2, MTA3, HDAC1 and HDAC2 levels in DU145 (Fig. 1B
and C) and LNCaP cells in a dose-dependent manner (Supplementary
Fig. 1).h up-regulation of PTEN and down-regulation of pAkt (Ser 473). Western blot analysis of
u145 and 50 μM and 100 μM for 22Rv1 cells) for 24 h. B). MTA1 is up regulated in prostate
/− cells for MTA1, PTEN, p-Akt (Ser 473), Akt and β-actin as loading control is shown.
ted with Ethanol (Ctrl) or resveratrol (Res, 50 μM) and lysates were probed for MTA1.
were ﬁxed, permeabilized and stained with anti-PTEN and anti-MTA1 primary antibody
bodies, respectively. Images were acquired using 63× objective on a Leica ﬂuorescent mi-
. Images showPTEN (green) both in nucleus and cytoplasm, and co-localizationwithMTA1
TEN in DU145 cells.Western blot analysis of cytoplasmic (Cyto) and nuclear (Nuc) lysates
r and cytoplasmic fractions, respectively. Subcellular localization shows exclusive nuclear
ially nuclear.
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prostate cancer cells: inverse correlation between MTA1 and PTEN
In conjunction with reports on transcriptional regulation of PTEN by
HDAC inhibitors [26] and by the MTA1/HDAC4 complex [27], coupled
with our own observation of resveratrol behaving as an HDAC inhibitor
(Fig. 1B), we found a signiﬁcant up-regulation of PTENmRNA upon res-
veratrol treatment in DU145 and 22Rv1 cells (Supplementary Fig. 2).
Importantly, resveratrol mediated down-regulation of MTA1 protein
levels was concomitant with up-regulation of PTEN protein and accom-
panied by a decrease in phosphorylated Akt (p-Akt, S473) levels in
DU145 and 22Rv1 cells suggesting an inverse relationship between
MTA1 and PTEN (Fig. 2A). To conﬁrm the inverse relationship between
these twomolecules, we examinedMTA1 expression inmurineprostate
epithelial cells from conditional Pten knockout mice and found that
Pten−/− cells express signiﬁcantly higher levels of MTA1 compared to
Pten+/+ cells (Fig. 2B) and that resveratrol inhibits MTA1 expression
in these cells (Fig. 2C) suggesting a possible negative co-relation be-
tween MTA1 expression and PTEN signaling.
In an earlier report by Salot and Gude, MTA1 and PTEN have been
shown to co-localize in the nuclei of breast cancer cells [28]. Our immu-
noﬂuorescence experiments revealed co-localization ofMTA1 and PTEN
in the nuclei of DU145 cells (Fig. 2D, Mander's overlap coefﬁcient =
0.73, Pearson's coefﬁcient = 0.84). Further experiments using confocalFig. 3.MTA1 knockdown enhances PTENwhile decreasing p-Akt which is augmented by HDAC
knockdown (MTA1 shRNA) cells either treated with Ethanol (Ctrl) or Trichostatin A (TSA, 300
upon MTA1 knockdown. DU145 EV or MTA1 shRNA cells were treated with DMSO (Ctrl), resv
300 nM) for 20 h. Cell lysates were immunoprecipitated with anti-PTEN antibody and
C) Quantitation for ratio of Ac-PTEN/PTEN was done using Image J software (NIH). EV (Ctrl) wa
tation for ratio of Ac-PTEN/PTEN in DU145 EV versusMTA1 shRNA cells is shown, *p b 0.05. Erro
depicted.microscopy also conﬁrmed nuclear co-localization of these two proteins
in addition to evident cytoplasmic localization of PTEN (Supplementary
Fig. 3). On the other hand, subcellular fractionation showed exclusive
nuclear localization for MTA1, HDAC1 and HDAC2 while PTEN was
mostly cytoplasmic with some amount in the nucleus (Fig. 2E). The
fact that MTA1 and PTEN can be detected in the nucleus suggested
that MTA1/HDACs co-repressor complex might be involved in post-
translational regulation/deactivation of PTEN, which in turn, can lead
to the activation of PI3K/Akt survival pathway. This ﬁnding substantiat-
ed the rationale to explore the crosstalk between MTA1 and PTEN and
the role of resveratrol in regulating this signaling.
3.3. PTEN activity is regulated by resveratrol-induced reversible acetylation
To further conﬁrm the inverse relationship between PTEN andMTA1
and to understand the role of theMTA1/HDAC deacetylase complex, we
treated DU145 MTA1-expressing (EV) and MTA1 shRNA cells with
HDAC inhibitor Trichostatin A (TSA) and performedwestern blot analy-
sis. MTA1 knockdown enhanced PTEN expression, which was further
augmented upon TSA treatment (Fig. 3A). Concomitantly, with increase
in total PTEN levels uponMTA1 knockdown, substantiated by TSA treat-
ment, there was a decrease in p-Akt (Ser 473). Interestingly, in addition
to expected inhibition of HDAC 1/2 activity, TSA treatment alone re-
duced MTA1 levels as well (Fig. 3A).inhibitor, TSA. A)Western blot analysis of lysates fromDU145 empty vector (EV) or MTA1
nM) for 18 h is shown. B) Resveratrol enhances acetylation of PTEN which is augmented
eratrol (50 μM), Suberoylanilidehydroxamic acid (SAHA, 10 μM) and Trichostatin A (TSA,
western blot analysis performed with anti-acetyl-lysine and anti-PTEN antibodies.
s normalized to 1 and all values were calculated relative to Ctrl, *p b 0.05. (Inset) Quanti-
r bars indicate means+ SEM. Representative data from three independent experiments is
Fig. 4.MTA1 knockdown-induced acetylation of PTEN predominantly occurs in the nucle-
us of prostate cancer cells. A) DU145 EV andMTA1 shRNA cells were treatedwith Ethanol
(Ctrl) or Trichostatin A (TSA, 300 nM) for 20 h. Cell lysates were fractionated to obtain cy-
toplasmic and nuclear fractions as detailed inmaterials and methods. Cytoplasmic and nu-
clear extracts were immunoprecipitated using anti-PTEN antibody and analyzed by
western blotting using antibodies to acetyl lysine and PTEN. Erk1/2 and Lamin A were
used as loading controls for cytoplasmic and nuclear fractions respectively, Cyto Cyto-
plasm, Nuc Nuclear. Representative data from four independent experiments is shown.
B) Quantitation for ratio of Ac-PTEN/PTEN, *p b 0.05 indicates signiﬁcance of nuclear
ratio of Ac-PTEN/PTEN versus cytoplasmic determined by paired Student's T test. Histo-
gram prepared by calculating raw values obtained using Image J software (NIH). Error
bars indicate means + SEM.
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tive regulatory effect of MTA1/HDACs on PTEN, we treated DU145 EV
and MTA1shRNA cells with resveratrol and HDAC inhibitors, SAHA
and TSA and performed IP PTEN and western blot for acetyl lysine
(Ac-lysine). Resveratrol signiﬁcantly increased acetylated PTEN (Ac-
PTEN), almost to the sameextent as SAHAand TSA (Fig. 3B andC). Inter-
estingly, MTA1 knockdown alonewas sufﬁcient to signiﬁcantly increase
Ac-PTEN (Fig. 3C, inset, p b 0.05, Ctrl vs MTA1shRNA) suggesting that
resveratrol's effect on PTEN acetylation occursmainly throughMTA1 in-
hibition. Since TSA and SAHA in addition to inhibiting HDACs functions
also can directly inhibit MTA1 expression (Fig. 3A and data not shown),
it is possible that the observed effects with SAHA and TSA are also me-
diated through MTA1 and not only through HDACs. Collectively, these
results demonstrate that, all three agents resveratrol, SAHA and TSA,
may suppress deacetylation and increase acetylation of PTEN by
inhibiting each of the three proteins in the complex, although MTA1
knockdown experiments showed dominant role of MTA1 in PTEN
deacetylation. These data demonstrate the negative association of
MTA1/HDAC1/2 complex with acetylation-dependent activation of
PTEN. Further, resveratrol and HDAC inhibitors which target the
MTA1/HDACs complex, enhance acetylation of PTEN that, in turn may
inhibit Akt phosphorylation.
We noticed that in all our experiments treatment of MTA1
knockdown cells with SAHA and TSA did not induce an additive
effect on PTEN acetylation (Fig. 3C) although they did induce PTEN
expression (Fig. 3B input). We then asked whether HDAC1 or
HDAC2 or both are needed to mediate the effect on PTEN
deacetylation. As shown in Fig. 3B, HDAC class I inhibitors, which
can inhibit both HDAC1 and 2, increased PTEN acetylation. We
then used HDAC1-speciﬁc inhibitor (4-(dimethylamino)N-[6-
(hydroxyamino)-6-oxohexyl]-benzamide) and found that PTEN
acetylation was increased but to a lesser extent than when treated
with TSA and SAHA suggesting involvement of HDAC2 in addition
to HDAC1 in PTEN deacetylation (data not shown).
3.4. MTA1 knockdown induces accumulation of acetylated PTEN in the
nucleus of prostate cancer cells
Since we already observed co-localization of MTA1 and PTEN in the
nucleus of DU145 cells (Fig. 2D and E), we further hypothesized that for
MTA1 a nuclear protein, to deacetylate PTEN which is predominantly
cytoplasmic, would require an event most likely occurring in the nucle-
us. To answer this possibility, we fractionated cytoplasmic and nuclear
extracts from DU145 EV and MTA1shRNA cells treated with TSA and
subsequently performed IP PTEN and western blot for Ac-lysine. We
found that Ac-PTEN expression was increased in both cytoplasm and
nuclear compartments; however, the increase in the nuclear compart-
ment was more dramatic (Fig. 4A and B, Nuc vs Cyto, p b 0.05). Impor-
tantly, this effect was prominent in MTA1 knockdown cells, which
was further augmented upon TSA treatment (Fig. 4A and B). This data
clearly indicated that MTA1 knockdown favorably enhances acetylation
of PTEN largely in the nuclear compartment. Further, it indicated that
for such a mechanism to be functional a physical interaction between
MTA1 and PTEN itself maybe important. Therefore, we next raised the
question: does MTA1 interact with PTEN?
3.5. MTA1 does not interact with PTEN in prostate cancer cells
We and others have shown that MTA1 can be localized in both nu-
cleus and cytoplasm with predominance in nuclei in cultured cancer
cells and tissues [13,29–33]. In our studies with tissue microarrays
of 291 human prostate cancer specimens, MTA1 nuclear localization
was directly correlated with aggressiveness of prostate cancer and
metastasis [13]. HDAC1 and HDAC2 are mostly nuclear proteins and
in prostate cancer, nuclear HDAC1 overexpression has been reported
to be correlated with poor prognosis [34] and HDAC2 expressionhad highly signiﬁcant prognostic value [35]. This means that
deacetylation of PTEN by MTA1/HDACs complex most likely occurs
in the nucleus. Since by immunoﬂuorescence and subcellular fraction-
ation experiments we found that MTA1 and PTEN can co-localize in
the nucleus, we hypothesized that they could physically interact
with each other. However, reciprocal co-immunoprecipitation (Co-
IP) analysis for interaction between endogenous MTA1 and PTEN re-
vealed association between MTA1 and HDAC1 and HDAC2 but not
PTEN (Fig. 5A). Ectopic overexpression of MTA1, PTEN and HDAC1
by co-transfections of myc-MTA1, HDAC1-Flag and HA-PTEN in 293T
cells revealed no interaction between MTA1 and PTEN, consistent
with our results in DU145 cells (Fig. 5B). In addition, co-IP experi-
ments with ectopic overexpression of PTEN in PC3M cells that express
very high endogenous MTA1 revealed no detectable interaction be-
tween MTA1 and PTEN (not even under stringent conditions when
MG132, a proteasome inhibitor, was applied to block degradation of
MTA1 and increase the probability of interaction, data not shown).
3.6. MTA1 interacts with acetylated PTEN in the nucleus
Since we could not detect an interaction between MTA1 and PTEN,
we surmised over the possibility that MTA1/HDACs complex could
have more afﬁnity to interact with the acetylated form of PTEN and in
turn deacetylate it. To prove this hypothesis, we devised two experi-
ments. First, we boosted acetylation by co expressing HA-PTEN
Fig. 5.MTA1 does not interact with PTEN. A) Cell lysates from DU145 cells were immunoprecipitatedwith antibodies to MTA1, PTEN, HDAC1 and HDAC2 or IgG controls and analyzed by
western blottingwith corresponding antibodies. B) 293T cells were co-transfectedwithmyc-MTA1, HA-PTEN and HDAC1-Flag and cell lysates were immunoprecipitatedwith antibodies
to myc, PTEN and Flag followed by western blotting. Myc and Flag antibodies were used for detection of MTA1 and HDAC1, respectively. PTEN was detected using anti-PTEN antibody.
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acetyltransferases reported for PTEN acetylation [36,37], in PC3M
cells and performed IP-western blot to detect MTA1 and PTEN in the
IP elutes. We were able to detect an interaction of PTEN with MTA1
and vice versa in cells where acetylation of PTENwas enhanced exclu-
sively using myc-p300 construct (Fig. 6A). The acetylated status of
PTEN in these cells was concomitantly conﬁrmed in IP reactions
with Ac-lysine antibody and immunoblotting for PTEN (Fig. 6A). In-
terestingly, co-expression of PCAF did not induce acetylation of
PTEN and subsequently did not show an interaction between PTEN
and MTA1. These results indicated that MTA1 interacts with the acet-
ylated form of PTEN. Moreover, co-expression of myc-p300 and HA-
PTEN leads to a further inhibition of p-Akt levels as compared to ex-
pression of HA-PTEN alone, suggesting that acetylation of PTEN
leads to an increase in its lipid phosphatase activity (Fig. 6A, input).
In our second strategy, we sought to determine the acetylation site
(s) in PTEN that can be involved in the interaction between PTEN and
MTA1/HDAC complex. Lysine residues that have been reported to be
involved in PTEN acetylation (K125/128 and K402) [36,37] were re-
placed by either arginine (R) or glutamine (Q) to create acetylation
resistant and acetylation mimetic mutants, respectively. PC3M cells
were transfected with either wild type PTEN or mutant constructs
and IP-western blots were performed to detect PTEN in the lysates.
Our data showed that the K125/128Q acetylation mimetic PTEN mu-
tant construct exclusively interacted with MTA1 (Fig. 6B). There was
no interaction of MTA1 either with the acetylation resistant K125/
128R and K402R mutants or with the acetylation mimetic K402Qmu-
tant. In addition, the K125/128Q acetylation mimetic showed de-
creased p-Akt (Ser 473) expression, conﬁrming that acetylation of
PTEN on these residues enhances its lipid phosphatase activity(Fig. 6B, input). We conclude from the above data that MTA1 interacts
exclusively with PTEN which is acetylated at lysines 125 and 128 and
that acetylation on these lysines renders PTEN active, as reﬂected by a
reduction in p-Akt.
3.7. Resveratrol-induced tumor regression in orthotopic prostate cancer
xenografts is mediated through MTA1 inhibition and PTEN activation
In our previous study, in which we examined MTA1-dependent
tumor development and progression in PCa using orthotopic
mouse model, we found that resveratrol treatment and MTA1
knockdown signiﬁcantly inhibited tumor growth, progression,
local invasion and spontaneous metastasis [11]. Xenografts express-
ing MTA1shRNA exhibited signiﬁcantly reduced tumor growth at
week 5 post-transplantation of cancer cells [11]. Moreover, MTA1
knockdown sensitized cells to resveratrol resulting in additional re-
duction of tumor progression. Using prostate tissues from the same
experiment, we stained tumors for MTA1, PTEN and p-Akt and found
that treatment with resveratrol simultaneously with decreasing
MTA1 levels increased levels of PTEN in control tumors (Fig. 7). Fur-
ther, MTA1-knockdown xenografts express much higher levels of
PTEN compared to MTA1-expressing tumors, and that combination
of MTA1-knockdown with resveratrol treatment keeps PTEN levels
high. Unfortunately, since acetyl PTEN antibody is not commercially
available we were unable to examine levels of acetylated PTEN in
these tissues. However, as a readout of PTEN activity we examined
p-Akt levels and found that MTA1-knockdown and resveratrol-
treated tumors express lower levels of p-Akt compared to untreated
controls (Fig. 7). Consistent with the potent antitumor effects,
resveratrol-treated and MTA1-knockdown tumors showed reduced
Fig. 6.MTA1 interacts with acetylated PTEN. A) PC3M cells were transfected with empty vector (HA-pSG5L), HA-PTEN, HA-PTEN andmyc-p300 or HA-PTEN and Flag-PCAF plasmids. Ly-
sates were immunoprecipitated with anti-PTEN, anti-acetyl lysine and anti-MTA1 antibodies followed by western blot. B) MTA1 interacts with PTEN when it is exclusively acetylated at
lysines 125 and 128. PTEN mutant constructs K125/128R, K125/128Q, K402R and K402Q were prepared by site directed mutagenesis using the InFusion HD Cloning kit (Clontech) and
conﬁrmed by sequencing as detailed inmaterials and methods section. PC3M cells were transfected with mutant constructs, lysates were immunoprecipitated with anti-MTA1 antibody
and analyzed by western blot using anti-PTEN antibody.
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control mice as described earlier [11].
4. Discussion
Pharmacologically safe dietary compounds with epigenetic mecha-
nisms of action are of great interest for cancer chemoprevention and
therapy [38–40]. We identiﬁed resveratrol as a potent inhibitor of
MTA1/HDAC1 and re-activator of p53 acetylation in prostate cancer
cells [10]. Moreover, combined treatment of LNCaP prostate cancer
cells with resveratrol and HDAC inhibitor SAHA resulted in a profound
decrease of MTA1 and synergistic increase in acetylated p53 and apo-
ptosis [10]. Since resveratrol had little effect onMTA1mRNA,we sought
the posttranslational regulation ofMTA1.Our unpublished results imply
that resveratrol causes MTA1 degradation by ubiquitin–proteasome
system.
The aim of the present study was to further investigate
resveratrol's epigenetic properties, particularly, the MTA1-mediated
reversal of acetylation/activation of another tumor suppressor,
PTEN, the loss of expression of which or inactivation is frequently
found in prostate cancer [41]. We report here on resveratrol regulated
rescue of PTEN expression, acetylation, and activity through MTA1 in-
hibition, which corresponds to its increased ability to inhibit Akt
phosphorylation and cancer cell survival.
It has been shown that 30% primary and 60%metastatic tumors con-
tain some kind of PTEN alteration [42,43]. Low PTEN expression is asso-
ciated with an increased risk of lethal prostate cancer [44]. Consistentlyincreased Akt activation (p-Akt) is associated with high Gleason grade,
advanced disease and poor prognosis of prostate cancer [45,46]. Accord-
ingly, mice with prostate-speciﬁc loss of Pten develop stage-deﬁned
prostate cancer with high levels of p-Akt, which progresses to invasive
adenocarcinoma and occasionally lymph node metastasis [47]. Howev-
er, homozygous Pten deletion is not common in human prostate cancer,
suggesting that additional attenuation of the remaining allele caused by
its posttranslational regulation could be a signiﬁcant contributor for
cancer development and progression. Therefore, activation of the re-
maining allele by reversible epigenetic therapy can restore PTEN
activation.
Our original observation of inverse relationship between MTA1 and
PTEN in addition to resveratrol's ability to regulate both proteins posed
twomajor questions: First, sinceMTA1 is part of the deacetylatingNuRD
complex, does it negatively regulate PTEN by deacetylating it? Second,
what role does resveratrol play in MTA1-PTEN signaling?
We and others reported an up-regulation of PTEN protein levels by
resveratrol in prostate cancer [48,49]. In this study we have presented
evidence that not only up-regulation but activation of PTEN occurs, at
least in part, through resveratrol inhibition of components of NuRD
deacetylation complex. It has already been reported that TSA promotes
PTEN transcriptional activation by increasing acetylation of histones at
the PTEN promoter [26] and TSA treatment induced PTEN-mediated ap-
optosis in oral squamous cell carcinoma [50]. In our experiments, res-
veratrol increased acetylation of PTEN in MTA1 knockdown cells
similar to the effects of HDAC inhibitors, SAHA and TSA, indicating the
involvement of MTA1/HDAC complex in PTEN deacetylation.
Fig. 7. Resveratrol induces tumor regression in orthotopic xenografts accompanied by decreased MTA1 and pAkt expression which is enhanced upon MTA1 knockdown and medi-
ated via PTEN activation. Male nudemice were injected orthotopically with DU145-luciferase-tagged EV (Ctrl) or MTA1 knockdown (MTA1shRNA) cells and treated with 10% DMSO
(Ctrl) or 50 mg/kg bw/day resveratrol (Res). Upon sacriﬁce, 4 μm sections were prepared from formalin-ﬁxed parafﬁn embedded prostate tumors and stained using antibodies for
MTA1, PTEN, pAkt and Ki-67. Left, bioluminescent images of prostate tumors at week 5 are shown. Right, representative immunohistochemistry images of MTA1, PTEN, pAkt and
Ki67 in Ctrl EV, Res-treated EV, Ctrl MTA1shRNA and Res-treated MTA1shRNA tumors are shown, magniﬁcation (×200).
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HDACs 1 and 2 and our ﬁndings on MTA1 accumulation as a character-
istic of aggressive prostate cancer [13],MTA1-mediated deacetylation of
PTENmost likely occurs in the nucleus. On the other hand, “classic” lipid
phosphatase activity of cytoplasmic PTEN is attributed to its regulation
of Akt signaling and apoptosis, while nuclear PTEN plays other impor-
tant non-canonical roles such as chromosomal stability, DNA repair,
and cell cycle arrest [51–54]. Nuclear PTEN positively regulates DNA re-
pair through up-regulation of RAD51, independent of its phosphatase
activity [55]. Importantly, nuclear PTEN plays an important role in reg-
ulating p53 acetylation and activity [56] as well as p53-mediated G1
growth arrest, cell death, and reduction of reactive oxygen species pro-
duction [57].
Interestingly, Salot & Gude, reported a physical association of MTA1
with PTEN in breast cancer cells and a possible post-translational regu-
lation of PTEN byMTA1 [28]. However, our vigorous attempts to detect
physical interaction betweenMTA1 and PTEN in prostate cancer, breast
cancer and other cells did not yield any positive results.
Therefore, we envisioned a scenario in which MTA1 interacts with
acetylated subpopulation of PTEN in prostate cancer cells. Indeed,we vi-
sualized an interaction of PTENwithMTA1 and vice versa only upon en-
hancing acetylation of PTEN, induced speciﬁcally by overexpression of
p300 acetyltransferase (Fig. 6A). To our knowledge, this is the ﬁrst re-
port on PTEN acetylation by p300 acetyltransferase while an indirect
transcriptional regulation of PTEN by p300 was demonstrated through
acetylation of histone H4 by Pan et al. [26]. However, we did not see
this effect with PCAF overexpression which counteracts the work by
Okumura et al., where they showed that PCAF is responsible for PTEN
acetylation at Lys125 and Lys128, leading to inhibition of its lipid phos-
phatase activity [36].There are only two reports on PTEN acetylation which have identi-
ﬁed three acetylation sites (Lys 125 and 128 and Lys 402) but there is
a disagreement on the potential role of acetylation in regulating PTEN
function. Okumura et al. reported that the lipid phosphatase function
of PTEN is inhibited when Lys125 and Lys128 are acetylated by histone
acetyltransferase PCAF [36], whereas Ikenoue et al. showed that Lys
402 acetylation modulates PTEN interaction with PDZ domain-
containing proteins [42]. In our experiments, acetylation mimetic
PTENmutant K125/128Q revealed an exclusive interaction with endog-
enous MTA1 in PC3M cells (Fig. 6B).
We repeatedly observed an inhibition in p-Akt levels (Ser 473)
linked to an increase in PTEN acetylation upon MTA1-knockdown,
treatment with TSA and resveratrol, and overexpression of p300
acetyltransferase.
In retrospect, in the study by Okumura et al., acetylation mimetic
mutants K125Q and K128Q showed increased p-Akt thus suggesting
that acetylation on these lysine residues renders PTEN inactive. Howev-
er, intriguingly, the double acetylation resistant mutant K125/128R and
the double acetylation mimetic mutant K125/128Q, both showed simi-
lar enhanced levels of p-Akt which is difﬁcult to comprehend. We, on
the other hand, believe that since Lys125 and Lys128 residues are located
in the phosphatase domain of PTEN protein, acetylation of these resi-
dues in turn activates lipid phosphatase activity of PTEN protein as indi-
cated by decreased p-Akt levels (Fig. 6B, input). We further believe that
in addition to induction of lipid phosphatase activity, acetylation of
PTEN on these two residues is a prerequisite for its non-canonical nucle-
ar functions. Moreover, it is conceivable that MTA1/HDAC deacetylating
complexwill havemore afﬁnity towards an acetylated pool of PTEN that
is active and present in the nucleus as shown by our data, which follow-
ing an interaction with MTA1 gets deacetylated and subsequently loses
Fig. 8.Our results suggest amodel ofMTA1-mediated resveratrol regulation of PTEN/Akt pathway. In the absence of resveratrol,MTA1/HDAC complex is intact and localized in the nucleus
where it can bind to acetylated PTEN. As a result, PTEN becomes de-acetylated, inactive and either stays in the nucleus, however without tumor suppressive functions, or diffuses to the
cytoplasmwithout any negative consequence to Akt allowing ampliﬁcation in p-Akt activitywhich leads to cancer cell survival. In contrast, when treatedwith resveratrol, owing to down-
regulation of MTA1 and HDAC1/2 and as a result of MTA1/HDAC non-functionality, the acetylation of PTEN increases, which leads to enhanced lipid phosphatase activity of PTEN and its
nuclear function culminating in apoptosis and inhibition of Akt survival pathway.
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with acetylated PTEN and demonstrate acetylated PTEN as the active
form that inhibits p-Akt-associated survival pathways.
Finally we substantiated the functional relevance of enhanced PTEN
expression upon resveratrol treatment in orthotopic xenografts with
DU145 MTA1 knockdown cells in nude mice. Immunohistochemistry
analysis clearly revealed that both resveratrol treatment and MTA1
knockdown enhanced PTEN expressionwhile concomitantly enhancing
Ki-67 proliferative index (Fig. 7) and apoptosis as reported earlier [36]
and simultaneously lowering p-Akt expression (Fig. 7). Unfortunately,
speciﬁc acetylated PTEN antibodies are not commercially available
restricting our ability to examine acetylation/deacetylation status of
PTEN in prostate tissues.
Our results provide a plausible mechanism bywhich natural com-
pound resveratrol acts on reversing pathological epigenetic changes
mediated by co-repressor MTA1/HDAC complex in prostate cancer
(Fig. 8). In aggressive prostate cancer, when MTA1 and HDAC1 and
2 are overexpressed and co-localized in the nucleus forming active
suppressor unit and causing deacetylation of PTEN protein, tumor-
suppressive functions of nuclear PTEN are inhibited. Deacetylated
enzymatically inactive PTEN can also translocate to the cytoplasm
however without negative consequences on Akt signaling, allowing
accumulation of p-Akt and ultimately cancer cell survival. In the
presence of resveratrol, which inhibits MTA1 and HDACs and dissoci-
ates the complex, interaction between MTA1/HDAC and acetylated
PTEN is interrupted leading to accumulation of “free” acetylated
PTENwith tumor-suppressive functions such as chromosomal stabil-
ity, DNA repair and cell cycle arrest. Acetylated PTEN also can trans-
locate to the cytoplasm, resulting in repression of its downstream
Akt signaling pathway. In less aggressive prostate tissues, the pro-
portion of acetylated PTEN is higher in cytoplasm and p-Akt signal-
ing is inhibited, partly, due to low and inactive presence of MTA1/
HDACs which does not interfere or sequester PTEN by deacetylation.
Therefore, we believe that in aggressive prostate cancer, MTA1/
HDAC complex associates with nuclear acetylated subpopulation of
PTEN reducing its tumor-suppressive functions, although the mech-
anisms that regulate accumulation of acetylated PTEN in the nucleus
and its interaction with MTA1/HDACs are not yet understood. Thus,
we conclude that there is an inverse relationship between MTA1
and PTEN levels and propose that under resveratrol treatment
which deactivates MTA1/HDACs complex, PTEN regains its activity,
possibly by reversed acetylation, which leads to apoptosis &activation of p53 in the nucleus and inhibition of PI3K/Akt survival
pathway.
5. Conclusions
We report herein that resveratrol, a dietary compound found in
grapes and wine, exerts its anticancer activity in prostate cancer, at
least in part, through epigeneticmechanisms, includingposttranslation-
almodiﬁcation and reactivation of PTEN tumor suppressor. Our data in-
dicate that PTEN is inactivated in prostate cancer by a novel negative
regulator, MTA1/HDACs: the co-repressor complex deacetylates and in-
activates PTEN resulting in inhibition of its nuclear tumor suppressive
functions, such as apoptosis, cell cycle arrest, and p53 activation and
its cytoplasmic lipid phosphatase function such as down-regulation of
p-Akt. We discovered that resveratrol by targeting the MTA1/HDAC
complex is able to reverse this negative epigenetic effect and reactivate
tumor suppressor PTEN. Together, theseﬁndings underscore the impor-
tance of dietary compounds with epigenetic capacity and provide valu-
able awareness for future development of a combinatorial strategy for
prostate cancer chemoprevention and treatment involving resveratrol
and other MTA1/HDAC inhibitors.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.11.004.
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